FDA Class II Recall: MPRX, Inc. dba Medical Park Pharmacy Recalls Squaric Acid Solution Over Expired Components
MPRX, Inc. dba Medical Park Pharmacy initiated a Class II recall for one bottle of Squaric Acid 0.1% Topical Solution (Clinic) on December 18, 2019. The recall, terminated December 13, 2022, stemmed from compounding with expired components and labeling deficiencies. This highlights the critical need for rigorous quality control and adherence to Good Manufacturing Practices, even for small-scale compounding operations, to mitigate patient safety risks and regulatory penalties.
FDA Findings: MPRX, Inc. Recalls Squaric Acid Solution Due to Expired Components
On December 18, 2019, MPRX, Inc. dba Medical Park Pharmacy initiated a Class II voluntary recall, designated D-0816-2020, for one 30 mL bottle of Squaric Acid 0.1% Topical Solution (Clinic). This action, distributed within Texas, was prompted by critical quality control failures: the product was compounded using components that had exceeded their expiration dates, and the final product labeling exhibited incorrect or missing lot and/or expiration date information. Specifically, the affected lot was identified as 61380:42 with a 'Use by' date of May 4, 2020. For procurement directors and regulatory affairs heads, this event underscores the absolute necessity of stringent raw material management and precise labeling protocols, even within smaller compounding operations. Failure to adhere to these fundamental Good Manufacturing Practices (GMPs) can lead to product recalls, reputational damage, and potential patient safety risks, necessitating immediate corrective actions and impacting supply chain reliability. The FDA's classification of this as a Class II recall indicates that the use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This means that while the immediate risk was contained, the underlying process failures could have broader implications if not addressed.
Limited Supply Chain Impact and Regulatory Resolution for MPRX, Inc.
Given the specific details of this recall—a single 30 mL bottle of Squaric Acid 0.1% Topical Solution (Clinic) distributed solely within Texas—the direct impact on global supply chains and major pharmaceutical procurement operations is minimal. MPRX, Inc. dba Medical Park Pharmacy, located at 8230 Elmbrook Dr Ste 600b, Dallas, TX 75247-4144, appears to operate as a compounding pharmacy, which typically serves a localized patient base rather than large-scale commercial distribution. For business development executives, this scenario highlights the importance of due diligence when considering partnerships or acquisitions involving smaller, specialized entities, ensuring their quality systems meet industry standards regardless of scale. The recall was initiated voluntarily by the firm, indicating a proactive response to identified deficiencies. Importantly, the FDA officially terminated this recall on December 13, 2022. This termination signifies that MPRX, Inc. has completed all necessary corrective actions, including retrieving the affected product and implementing measures to prevent recurrence, satisfying the FDA's requirements. This outcome provides clarity for any potential partners or customers regarding the resolution of this specific regulatory issue, although continuous monitoring of compliance is always advised.
Broader Regulatory Vigilance in Compounding and Pharmaceutical Manufacturing
While the MPRX, Inc. recall was limited in scope, it serves as a reminder of the FDA's unwavering vigilance across all segments of the pharmaceutical industry, including compounding pharmacies. For supply chain VPs and regulatory affairs heads, this incident reinforces that no operation, regardless of its size or distribution footprint, is exempt from rigorous quality and labeling compliance. The FDA consistently monitors for deviations from GMPs, whether it involves a single compounded bottle or large-scale manufacturing batches. This continuous oversight is evident in other recent regulatory actions, such as the FDA Class II Recall concerning Essential Wellness Pharma's Progesterone Injection for sterility assurance failures, or the FDA hearing impacting Amgen's Tavneos market future. These parallel events, though unrelated to MPRX, Inc., collectively demonstrate the agency's commitment to patient safety and product integrity. Companies must therefore maintain robust internal audit programs, conduct regular risk assessments, and ensure personnel are adequately trained on current GMPs to proactively identify and mitigate potential compliance gaps. Investing in comprehensive quality management systems is not merely a regulatory obligation but a strategic imperative to safeguard brand reputation and ensure uninterrupted market access.